my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
30-12-2010: Swedish Orphan Biovitrum announced that it has returned full development rights to Symphogen, co-developer of Sym001, for ITP (Immune Thrombocytopenic Purpura) treatment and for HDN (Hemolytic Disease in Newborn) prophylaxis, for strategic reasons.
Sym001 is currently in clinical phase II for treatment of ITP and in ADP (anti-D Prophylaxis) to prevent HDN. The Sym001 program is based on Symphogen's recombinant polyclonal technology and has been jointly developed since 2006, from early preclinical to its current clinical phase. Swedish Orphan Biovitrum (Sobi) has now decided to opt out of the program to be able to focus fully on its late-stage development pipeline.
"We have appreciated the collaboration with Symphogen on this novel program which may offer patients significant value in the future. With a maturing pipeline we have, however, been forced to prioritize the delivery of our late stage development portfolio", said Peter Edman, CSO of Sobi.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Merck Expands EGFR Targeted Portfolio
Merck announced that an exclusive worldwide license agreement was signed with Symphogen A/S for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). Sym004 is currently being evaluated in a Phase I/II trial for the treatment of patients with adv ... more
Swedish Orphan Biovitrum returns development rights to Sym001 to Symphogen
Swedish Orphan Biovitrum announced that it has returned full development rights to Symphogen, co-developer of Sym001, for ITP (Immune Thrombocytopenic Purpura) treatment and for HDN (Hemolytic Disease in Newborn) prophylaxis, for strategic reasons. Sym001 is currently in clinical phase I ... more
Symphogen and Swedish Orphan Biovitrum receive U.S. orphan drug designation for Rozrolimupab in ITP
Symphogen and Swedish Orphan Biovitrum announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to rozrolimupab (Sym001) for the treatment of primary Immune Thrombocytopenia (ITP). ITP is an autoimmune bleeding disorder characterized by abnorma ... more
Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases. more
FDA approves Kineret for the treatment of NOMID
Sobi announced that the US Food and Drug Administration (FDA) has approved Kineret® (anakinra) for the treatment of children and adults with neonatal-onset multisystem inflammatory disease (NOMID). Kineret® is the FDA-approved therapy for NOMID, the most severe form of cryopyrin associated ... more
Biogen Idec and Sobi announce positive top-line results from phase 3 study in hemophilia B
Biogen Idec and Swedish Orphan Biovitrum (Sobi)announced positive results from B-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia B. Hemophilia B is a rare inherited disorder that impairs blood coagulation.Top-line results from B-L ... more
Biogen Idec and Swedish Orphan Biovitrum announced the initiation of two global pediatric clinical trials of the companies' long-lasting recombinant Factor VIII and Factor IX Fc fusion proteins (rFVIIIFc and rFIXFc) in hemophilia A and B.rFVIIIFc and rFIXFc are fully-recombinant clotting fa ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
